OptimizeRx plans new independent director in H2 2025; Whetstone withdraws nomination notice

OptimizeRx Corp

Plans to add a new independent director in H2 2025 as part of ongoing board refreshment.
Whetstone Capital Advisors withdrew its March 6 director nomination notice after constructive engagement.
Current board has five members; three new directors added since 2020 including Klema (2024) and Wasson (2020).
Chairperson Lynn Vos cites progress under CEO Steve Silvestro and commitment to recruiting qualified directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.